Fig. 3.
Mevastatin sensitivity in AML cell lines is associated with sensitivity to other cholesterol-modulating treatments.
(A) The fraction of sub-G1 apoptotic cells, as determined by flow cytometry, is shown for NB4 and KG1a cells untreated (UN) or treated with mevastatin (MEVA; 5, 25, or 50 μg/mL) for 24 hours. NB4 cells were sensitive to all treatments, while KG1a cells were relatively resistant. Data are presented with standard errors and represent the mean of 2 to 5 independent replicates. (B) The fraction of sub-G1 apoptotic cells, as determined by flow cytometry, is shown for NB4, HL60, and KG1a cells untreated (UN) or treated with mevastatin (MEVA; 50 μg/mL), cholesterol esterase (CE; 0.1 μM), or cholesterol oxidase (CO; 0.1 μM) for 24 hours. NB4 cells were sensitive to all treatments. HL60 cells were sensitive to CE and CO and modestly sensitive to MEVA. KG1a cells were relatively resistant to all cholesterol-modulating treatments. Data are presented with standard errors and represent the mean of 2 to 5 independent replicates.